Service was Opko Health’s largest product and service line in fiscal 2025, bringing in $222.74M of $550.64M (40%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare Insurers | — | — | — | |||||||
| Service | $415.73M | $304.94M | $222.74M | |||||||
| Revenue From Services | — | — | — | |||||||
| Client Payors | — | — | — | |||||||
| Client Payers | — | — | — | |||||||
| Transfer Of Intellectual Property & Other | $180.70M | $107.40M | $79.68M | |||||||
| Revenue From Transfer Of Intellectual Property & Other | — | — | — | |||||||
| Product | — | $155.11M | $156.92M | |||||||
| Products | — | — | — | |||||||
| Rayaldee | $67.55M | $69.30M | $59.39M | |||||||
| Royalty | — | — | $31.90M | |||||||
| Patients | — | — | — | |||||||
| Germany Price Approval By Local Sick Fund Association | — | — | — | |||||||
| Non-Dravet Syndrome Products | — | — | — | |||||||
| First Marketing Approval Of Rayaldee In Europe | — | — | — | |||||||
| Total | $663.98M | $636.75M | $550.64M |
Opko Health brought in $550.64M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. That is less than the $606.88M it reports by geography, so these lines do not cover all of its revenue. Service was the largest at $222.74M (40.5%), ahead of Product at $156.92M (28.5%) and Transfer Of Intellectual Property & Other at $79.68M (14.5%). The other two lines brought in $91.29M combined.
Compared with fiscal 2024, Product grew fastest, up 1.2% to $156.92M, while Service fell the most, down 27.0% to $222.74M. Some of that change comes from Opko Health regrouping its lines.
Opko Health began breaking out Royalty in fiscal 2025, when it brought in $31.90M.
United States was Opko Health’s largest region in fiscal 2025, bringing in $436.06M of $606.88M (72%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2014 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $597.82M | $546.30M | $436.06M | ||||||||||
| U.S | — | — | — | ||||||||||
| Total Revenues | — | — | — | ||||||||||
| Ireland | $141.47M | $48.40M | $51.40M | ||||||||||
| Chile | $68.49M | $65.05M | $62.38M | ||||||||||
| Spain | $23.52M | $24.63M | $26.73M | ||||||||||
| Mexico | $20.22M | $23.87M | $25.52M | ||||||||||
| Israel | $9.74M | $1.77M | $522.00K | ||||||||||
| Other Countries | $2.25M | $3.12M | $4.27M | ||||||||||
| Other | — | — | — | ||||||||||
| Total | $863.50M | $713.14M | $606.88M |
Opko Health brought in $606.88M from its seven regions in fiscal 2025, the year ended December 31, 2025. That was down 14.9% from $713.14M in fiscal 2024. United States was the largest at $436.06M (71.9%), ahead of Chile at $62.38M (10.3%) and Ireland at $51.40M (8.5%). The other four regions brought in $57.04M combined.
Compared with fiscal 2024, Spain grew fastest, up 8.5% to $26.73M, while United States fell the most, down 20.2% to $436.06M. From fiscal 2023 to 2025, combined revenue from these regions fell from $863.50M to $606.88M, a compound annual decline of 16.2%. United States' share of the total rose from 69.2% to 71.9%.
Diagnostics was Opko Health’s largest segment in fiscal 2025, bringing in $370.28M of $527.20M (70%).
| Statement Business Segments | FY 2011 | FY 2012 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $515.28M | $480.67M | $370.28M | ||||||||
| Pharmaceuticals | $180.66M | $155.11M | $156.92M | ||||||||
| Pharmaceutical | — | — | — | ||||||||
| Total | $695.94M | $635.78M | $527.20M |
Opko Health brought in $527.20M from its two segments in fiscal 2025, the year ended December 31, 2025. That is less than the $606.88M it reports by geography, so these segments do not cover all of its revenue. Diagnostics was the largest at $370.28M (70.2%), ahead of Pharmaceuticals at $156.92M (29.8%).
Compared with fiscal 2024, Pharmaceuticals grew 1.2% to $156.92M, while Diagnostics fell 23.0% to $370.28M.
Opko Health (OPK) reports its revenue by product and service, by geography and by statement business segments. In fiscal 2025, Service was its largest product and service line, bringing in $222.74M (40.5% of the total), followed by Product at $156.92M (28.5%).
Service was Opko Health's largest product and service line in fiscal 2025, bringing in $222.74M, or 40.5% of the $550.64M total across its five product and service lines.
United States was Opko Health's largest region in fiscal 2025, bringing in $436.06M, or 71.9% of the $606.88M total across its seven regions.
Diagnostics was Opko Health's largest segment in fiscal 2025, bringing in $370.28M, or 70.2% of the $527.20M total across its two segments.
Among Opko Health's regions that make up at least 2% of revenue, Spain grew fastest in fiscal 2025, up 8.5% from $24.63M to $26.73M.
Every figure comes from Opko Health's annual financial filings, as reported. Each line keeps the name Opko Health gives it, and years follow its fiscal calendar.
Opko Health's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.